NLS Agreement

The company has signed an agreement with Dexcel Pharma USA, to divest the full rights to Zubsolv (buprenorphine/naloxone) sublingual tablet CIII, for the treatment of opioid use disorder, in the US.

Camurus and Gubra have entered into an exclusive collaboration and license agreement aimed at creating a long-acting therapeutic option for the treatment of hypoparathyroidism.

Nanexa will receive an upfront payment of USD 3 million and is entitled to up to USD 500 million in potential milestone payments as well as a tiered single-digit royalty on product sales.

The company has signed an agreement with an IDN (Integrated Delivery Network) in the Western US, marking the company’s most significant opportunity for sales growth in the region to date it states.

The agreement includes an upfront payment of USD 14 million, as well as potential clinical, regulatory, and commercial milestone payments totaling up to USD 400 million.

FluoGuide is in advanced negotiations with a world leading medical technology company on a collaboration agreement within head and neck cancer surgery where the aim is to optimize the usage of imaging systems and FG001 to enable better treatment for patients with cancer.